A Republican bill with no cosponsors
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "Growing America's Pharmaceutical Supply Act" or the "GAP Supply Act," seeks to amend section 503B of the Federal Food, Drug, and Cosmetic Act. The primary goal is to help outsourcing facilities better manage drug shortages. It does this by allowing these facilities a short-term period to keep supplying the market after a drug has entered a shortage. The amendment changes specific language regarding timing to include a 180-calendar-day window.
Yes· 3 of 5
- Scored +3
Does this make health care easier to get in general?
The bill aims to mitigate drug shortages, which helps ensure patients can consistently access necessary medications.
- Scored +2
Would people over 65 be better off under this?
Seniors often rely on regular medication supplies, which this bill seeks to protect by mitigating shortages.
- Scored +2
Would households on low incomes be better off under this?
Improving drug supply stability can help prevent cost increases that disproportionately affect low-income households.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Enhanced ability to mitigate drug shortages: The bill aims to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market. This is found in the introductory text and Section 2.
-
Extended supply window: By striking "at the time" and inserting "within 180 calendar days" in subsection (a)(2)(A)(ii) and subsection (d)(2)(A), the bill allows for a broader timeframe for distributing drugs during a shortage. This is found in Section 2.
Potential Negative Impacts for People
- No negative impacts are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Improving drug supply stability can help prevent cost increases that disproportionately affect low-income households. Would retired people be better off under this? — The bill's focus on mitigating drug shortages provides greater security for retirees who depend on consistent medication access. Would people over 65 be better off under this? — Seniors often rely on regular medication supplies, which this bill seeks to protect by mitigating shortages.
- Healthcare
- Does this make health care easier to get in general? — The bill aims to mitigate drug shortages, which helps ensure patients can consistently access necessary medications. Does this lower the price of prescription medicines? — By allowing outsourcing facilities more time to supply the market during shortages, the bill may help stabilize availability and prevent price spikes driven by scarcity.
- 2/12/2026
- Referred to the House Committee on Energy and Commerce.
- Introduced in House